For many patients with gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) remain the treatment of choice, according to David Armstrong, MA, MB, BChir, FRCP (UK), FRCPC, FACG, AGAF, and colleagues. “However, despite PPI therapy, many patients with GERD continue to be symptomatic,” they write.
Trending
- Natera acquires Foresight Diagnostics for up to $450M (Medtech Dive)
- $4.2M CDC grant to increase colorectal cancer screening in Pennsylvania (PennState)
- Motility coding changes coming in the new year (AGA)
- Updated Crohn’s Disease Guideline Stresses Early Use of Advanced Drugs (Medscape)
- Check your final 2025 MIPS eligibility (AGA)
- Affordable Care Act subsidies appear likely to expire (Chief Healthcare Executive)
- AI scribes hold ‘transformative potential’ for improving physician burden, patient care (Healio)
- New York Gastroenterology Associates Taps Proscia for Digital Pathology (Bio.IT World)
